Experts in Sterile Compounded Solutions
JCB is registered with the FDA as a 503B Outsourcing Facility. Registration with the Food and Drug Administration for compounding pharmacies is voluntary and all registered facilities are subject to FDA inspections.

JCB Labs Blog


Compounded Sterile Products-Higher Standards and Increased Patient Safety

Posted By Greg Rockers on Tue, Feb 24, 2015 @ 09:02 AM

In the world of sterile compounding, much has changed over the last two years.  Prior to the passage of the Drug Quality and Security Act (DQSA) in November 2013, USP 797 was the quality standard for compounded sterile products (CSPs).  Now that the DQSA has passed, providers have the option of getting their CSPs from 503B Outsourcing Facilities (OF) that must follow current Good Manufacturing Processes (cGMP).   This significantly higher cGMP standard is preferred among physicians, pharmacists and nurses who want to make sure they give their patients CSPs of the highest possible quality.  In fact, both the FDA and CMS have stated their preference that providers purchase CSPs only from FDA registered 503B Outsourcing Facilities. 

 One significant change that is a result of becoming a 503B Outsourcing Facility is the CSP testing requirements. The requirements are so much more than simply sterility, endotoxin and potency testing. The level of rigor, suitability and specificity is significantly higher. The sterility test must comply with United States Pharmacopeia (USP) 71, the endotoxin test must comply with USP 85 and the potency tests must be based on the compendial method described in the products’ USP monograph.   Make sure your CSP provider is performing these tests at the required level and make sure you ask your Outsourcing Facility for these test results!

 As a consequence of the cost and lengthy time requirements of this level of testing, the days of compounding sterile products one, two or even fifty at a time are over.  To maximize efficiency, control costs and ensure consistent, high-quality products, Outsourcing Facilities must produce their products in larger batches.  JCB Laboratories’ has decreased its’ formulary of products and invested considerable time and resources into manufacturing processes to make sure all products meet the highest standard.  That is the JCB commitment to your patients and that is what I call value!

 While, in rare cases, this may mean the product you used to get from JCB is no longer available, it certainly does not mean we are not innovating, researching and compounding new products. We have been and always will be a dependable, reliable source for innovative new compounds and for drug shortage products.  As you go to conferences and learn about new CSP options or when a drug shortage has an adverse effect on your ability to take care of patients, let us know. We welcome the opportunity to compound CSPs that you need the most.

Your Partner,

 

Greg Rockers. R.Ph.

VP-Business Development

Tag: Sterile Compounding, USP 797, Quality, Partnership, 503B, compounding, outsourcing facility, FDA, cGMP, CMS, DQSA, innovating,

Bigger, Faster, Stronger

Posted By Brian Williamson on Tue, Feb 17, 2015 @ 12:02 PM

In our last blog, we shared with you that we would have some exciting news.  We would like to introduce you to the BIGGER, FASTER, STRONGER JCB Laboratories that you have come to know and respect. 

 

BIGGER!  FASTER!  STRONGER!  These three words describe JCB Laboratories in 2015.  We have begun the development and construction of a new sterile manufacturing facility in Wichita, KS.  This new facility will truly be a one-of-a-kind 503B Human Drug Outsourcing Facility committed to the safety of your patients.  There are too many unique features to mention in this article so you will have to come to Wichita and see it for yourself!  Some of the highlights include:

 

BIGGER!

 

The new facility will be six times BIGGER than the current facility and will comprise a whopping 49,000 square feet.  It will include many new features never seen before in the sterile compounding industry, including redundant operating systems and larger areas for order fulfillment. 

 

FASTER!

 

Automation is a key component incorporated into the design of the operations.  Not only is automated equipment FASTER than traditional manual processes, it is also safer than human intervention.  JCB Labs will rely heavily on custom robotic equipment, closed-system sterile filling machines, and continuous monitoring of all areas of production. 

 

STRONGER!

 

JCB has invested heavily in top talent individuals who perform on a high level at all times.  This tradition of attracting, training, and maintaining high-quality performers has made us stronger over the years.  We will continue to attract people who have a desire to work smarter, harder, and with a high level of determination.  JCB is STRONGER because of its people, its culture and desire to service our partner clients. 

 

We are very excited about 2015!  We understand that our partner clients are the reason we have been successful.  You should expect nothing less than the BIGGEST, FASTEST, and STRONGEST provider of safe compounded sterile products...off to the races!

 

Brian Williamson, PharmD

President

Tag: 503B, BIGGER! FASTER! STRONGER!, New Facility, 503B Human Drug Outsourcing Facility, Automation, Determination,

Partners

Posted By Brian Williamson on Fri, Feb 13, 2015 @ 10:02 AM

People buy from those they like and trust.  It’s a fact!  Think about it.  We don’t have the luxury today of wasting time buying from people who aren’t truthful, transparent, and forthright.  This is especially true in the healthcare industry.  It is not just our dollars at stake if we make bad buying decisions...our patients can suffer if we choose poorly. 

 

From now on, JCB will refer to our “customers” as PARTNERS.  Partners help each other grow and flourish.  Partners look out for each other and ensure that their respective businesses are successful.  Partners share success in many ways.  If you partner with a company that is truthful, transparent, and forthright, you can rest assured that you will be successful.  Your success will be evident by repeat patient visits, the referrals your patients will give, and the reputation that you will develop.  Communication is also key to a successful partnership.  Over the years, JCB has developed very successful partnerships based on our ability and desire to ask questions about your practice, provide sound clinical information, and keep our partners up to date on changes and innovation.  We look forward to developing new partnerships and strengthening current relationships. 

 

We have some very exciting news to share with you in our next communication.  Please check your email over the next couple of days for an announcement that will solidify JCB Laboratories as the leader in sterile compounded products. 

 

Your Partner,

Brian Williamson, PharmD

President

Tag: Quality, Integrity, Partnership, Success, Trust, Transparent, Truthful, Forthright,

New National Sales Director

Posted By Greg Rockers on Wed, Feb 11, 2015 @ 08:02 AM

To our valued partners:

I am pleased to announce Steve Strickland as the new National Sales Director for JCB Laboratories.  Steve has over 20 years of experience in the pharmaceutical industry in a variety of roles and is a tremendous addition to the JCB team.  With his considerable sales leadership experience, I am confident you will find Steve a welcome resource.  His record of success is a clear indication of his commitment to providing excellent customer service with uncompromising integrity.  Steve’s values are a perfect fit with the JCB commitment to deliver the safest, highest quality products to your patients. 

This commitment to quality is something you have come to know over the past decade and is the hallmark of JCB Laboratories.  Unmatched customer service is a pillar to that commitment.   Steve looks forward to enhancing our mutual partnership through an expanded direct account management team which will further improve our first in class service you have come to expect and deserve.

In the coming weeks, Steve and his sales team look forward to the opportunity to meet you and continue to develop the trust you have placed in JCB Laboratories.

We appreciate your business!

 

 

Greg Rockers, R.Ph.

VP-Business Development

Tag: Customer Service, Quality, Integrity, Partnership, Experience, Leadership,

Sales Team Changes

Posted By Brian Williamson on Tue, Feb 10, 2015 @ 16:02 PM

You may have noticed that we made some changes to our sales team in December.  We had a very successful and talented group of sales people.  Due to conditions out of our control, we had to reorganize our team.  This meant, unfortunately, that we released our entire team from service.  We wish the former sales team much success in their future careers.  We have seen communication from some of our clients that in fact some of the former sales team members have found opportunities at other sterile compounders.  Once again, we wish them and their employers much success in today’s highly regulated environment of sterile compounding. 

 

JCB has never been the “bargain basement” provider in the industry and we don’t intend to be the low-cost provider.  We will remain competitive on pricing as much as safety for your patients will allow.  JCB will not sell a product at a price that would indicate corner cutting practices, lack of respect for your business and reputation, or simply to compete with other providers who may not have identified their true value proposition.  Think about it...do you really want the cheapest product on the market?  Next time one of your vendors (any vendor, not just sterile compounders) comes to you with price as their only value proposition think about all that is missing in that deal. 

 

As you know, the Drug Quality and Security Act (DQSA) signed into law by President Obama on November 27th, 2013 was a significant regulatory achievement.  It allowed for sterile compounders to voluntarily register with the FDA as an Outsourcing Facility.  JCB is one of only 41 registered Outsourcing Facilities.  Registration as an Outsourcing Facility (503B Outsourcing Facility) comes with the expectation that the registrant will comply with Good Manufacturing Practices (GMP).  These are the same set of regulatory compliance practices that large sterile pharma companies must comply with.  As you might imagine, complying with GMP regulations is an extremely expensive and expertise-intensive endeavor.  JCB has charged ahead with excitement and enthusiasm and is “all in” on this new era of sterile compounding. 

 

The regulations in place today are there for a reason...to protect patient safety.  You face the same reality in patient care.  Why do patients continue to come back to your facility and refer friends and family to you?  Because you have shown them that even though you may not be the cheapest provider, you do have a strong value proposition...patient safety and world-class care. 

 

Please look for an email introducing JCB’s new National Sales Director, Steve Strickland.

 

Brian Williamson, PharmD

President

 

Tag: 503B, outsourcing facility, cGMP, DQSA, price, Continuous quality Improvement,

Consolidating Standing Orders in an Ophthalmic Surgery Center

Posted By Greg Rockers on Wed, Oct 29, 2014 @ 16:10 PM

I could have also given this blog the title, “Help, I am a consultant pharmacist and I have a director of nursing that is going crazy trying to keep up with a group of surgeons who each want a different pre-op standing order for cataract surgeries!”

I speak to nurses at surgery centers every day. A common topic of conversation is the issues that can arise when every surgeon wants a different regimen of pre-op dilating and numbing drops prior to a cataract procedure. Most understand  why a physician wants to stick with his/her protocol.  It works for them and this is the way they have been doing it for years! However, in today’s ambulatory surgery center (ASC) world, where reimbursement continues to shrink, surveyors are vigilant and lawsuits are not uncommon, finding ways to increase efficiency, lower costs and reduce risk is critical.  

This brings me back to the consultant pharmacist.  The nurse in question had a great consultant pharmacist who was ready and willing to help her tackle this problem. When the pharmacist offered to help, the nurse handed the consultant 30 pages of standing orders. Both realized that this situation was untenable.  The facility was wasting valuable nursing time trying to find the correct meds for the different orders, spending 30 to 45 minutes giving a series of 3-4 individual drops up to 3 different times and the rate of medication wastage was high.  Additionally, there was a real fear  that a medication mix-up was inevitable.  

The nurse and the pharmacist got together and committed to fixing this problem. They went through each order and found that, from a clinical perspective, there really was not significant differences in the vast majority of the orders. They decided to call their compounding pharmacy to find a combination ophthalmic drop that would work for most of their surgeons, and present it at the next meeting.

It took a little convincing but the proof was in the results. Having just one or two different pre-op eye drop combinations allowed the facility to streamline the medication ordering and administration process.  The surgeons got the results they wanted and the nurses were able to shave almost 30 minutes off of their normal pre-op time.  This also made the surgeons happy because the shorter pre-op time allowed them to schedule more cases per day.

Change can be challenging for everyone.  In this case, the nurse and pharmacist had good data that showed their proposal would result in therapy that was safer, more efficient and cost effective.  This was a winning solution for everyone - physician, nurse, patient and facility!

Tag: combination, compounding, cataract, surgeries, dilating, ASC,

Customer Collaboration and Feedback

Posted By Greg Rockers on Thu, Oct 09, 2014 @ 09:10 AM

The absolute favorite part of my job is interacting with our customers. Every day brings a unique situation - some good, some not so good, but all important. Feedback from customers is crucial to any business and it is certainly true in the world of sterile compounding. It is amazing what I learn from conversations with physicians, nurses, administrators and buyers.  

I have a yellow legal pad on my desk and take notes when speaking with customers. It is very helpful to have a record of my day and I routinely review those notes.  This really helps in identifying patterns.

Drug shortages are a great example.  Those of you reading this blog often find out about drug shortages before they become an issue nationally. When you call JCB and talk to me, our customer service representatives or our sales team concerning a need, we all share that with each other. When we talk to other customers, we ask them if they are experiencing similar issues. This allows us to get out in front of a drug shortage and start production earlier so you do not run out of a critical medication. We are going to start sending out a drug shortages email blast once a week with drugs we are compounding in response to shortages.

New and popular products. Sometimes, your feedback leads to the formulation of a new product.  For example, customers call us and ask if we can combine two or more products into one compound to make administration more efficient.  Our cataract surgery, preoperative combination dilation drops are a great example of this. So, in addition to the drug shortages email blast, we will also send out a regular email with information on new and popular products we compound.

(If you want to receive either of the emails described above, send us an email at info@jcblabs.com and we will add you to our email list. Also, I plan to share tidbits and best practices on a regular basis and publish them in this blog space. Do not hesitate to contact me at greg@jcblabs.com with ideas, questions or concerns. You are the reason we are here!)

Tag: collaboration, drug shortages, combination, cataracts, cataract surgery,

ProPharma

Posted By Brian Williamson on Thu, May 22, 2014 @ 17:05 PM

In January, JCB registered with the FDA as an 503B Outsourcing Facility. This registration indicates our commitment to patient safety and acknowledges that a higher level of compliance and oversight is welcomed. We also understand that in order to continue providing sterile compounded products to facilities across the country, it was necessary to align our processes more closely with current Good Manufacturing Practices (cGMP). While JCB has always incorporated cGMP thinking within our facility, it was time to raise the bar again.  

In December, 2013, JCB contracted with one of the top cGMP compliance companies in the country, ProPharma Group, to improve overall compliance and robustness of our practices. ProPharma (PPG) performed a gap analysis to determine where we stood in regards to cGMP compliance. After the assessment, JCB contracted with PPG to be onsite at JCB writing new protocols, validating and revalidating equipment, and performing quality studies on JCB’s overall processes. The performance and execution of the project was flawless and PPG performed at a level much higher than expected.  While this was only the initial phase of ongoing Continuous Quality Improvement and cGMP compliance, JCB and PPG worked together to achieve the goal that is and has always been priority number one...product reliability and patient safety.  

Tag: Quality, cGMP, Continuous quality Improvement, ProPharma,

FDA and State Registration for Outsourcing Facilities

Posted By Brian Williamson on Fri, May 16, 2014 @ 11:05 AM

The passing of the Drug Quality and Security Act (DQSA) in November of 2013 was one of the most significant events in the compounding industry in decades.  The DQSA came to fruition after many months of debate and controversy over who had authority and jurisdiction over sterile compounding pharmacies. The result was that a sterile compounding pharmacy could voluntarily register with the FDA as a 503B Outsourcing Facility.  According to the DQSA, this type of registration allows a sterile compounding pharmacy to ship products via interstate commerce without the need for specific patient prescriptions.  However, it does place the pharmacy squarely under the jurisdiction of the FDA and subjects the facility to current Good Manufacturing Practices (cGMP).  cGMP are the regulations that large pharmaceutical manufacturing firms must adhere to in their daily practices.  Complying with cGMP can be a daunting task and not every sterile compounder will elect to register as an Outsourcing Facility.  

In reality, after 6 months under the DQSA, very little has changed. There are still many things evolving regarding federal and state enforcement of the Act.  It will likely take several more months to determine how the FDA and State Boards of Pharmacy will work together to enforce compliance.  It is clear that many State Boards of Pharmacy will require registered Outsourcing Facilities to register in their state as either drug distributors, wholesalers, manufacturers or, in some cases, all three!  In addition, some states are requiring that Outsourcing Facilities have a pharmacy license in their state, while the DQSA stated that an Outsourcing Facility didn’t even have to be a pharmacy?!  

What is not clear is whether the FDA registration will override State Boards of Pharmacy requirements.  JCB is actively pursuing all appropriate registration in each state to ensure that we stay in compliance and are able to continue shipping product to health care providers. This process will take some time but we have made significant progress. We started with states that require prescriptions for products being administered to patients within a healthcare facility in an effort to help them become more efficient as soon as possible.  JCB is contacting current clients in those states where the appropriate registration has been obtained and approved.  Clients have been very excited and relieved.  We will continue to keep you updated on any changes that occur related to individual state boards or with the FDA.    

Tag: 503B, outsourcing facility, FDA, DQSA, State Boards of Pharmacy,

Outsourcing Facilities (503B) and cGMP

Posted By Brian Williamson on Wed, Mar 12, 2014 @ 16:03 PM

The definition of high-risk sterile compounding is “Starting with a non-sterile Active Pharmaceutical Ingredient (API) and creating a sterile product.”   We have written many articles about how important quality is in high-risk sterile compounding.  JCB Labs has gone to great lengths and considerable expense to develop a facility and processes that satisfy cGMP practices and are capable of producing a sterile product every time.  This is what the FDA expects from pharmacies that, like JCB Labs, are registered as 503B Outsourcing Facilities.

Please go to this link to see a very well written article concerning the importance of vetting your high-risk compounding pharmacy. The information might be invaluable to you and your facility as you decide where to get your compounded products.

Tag: Outsourcing, 503B, outsourcing facility, cGMP, sterile,